1. FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication;Food and Drug Administration,2017
2. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 study;Marabelle;J Clin Oncol,2020
3. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer;Makker;J Clin Oncol,2020
4. National Comprehensive Cancer Network. Uterine Neoplasms (Version 3.2019). Accessed online May 2019.
5. Disparities in timeliness of endometrial cancer care: a scoping review;Najor;Obstet Gynecol,2023